
501c3 & 501c6 nonprofit est. 2024 to protect Minnesota's independent pharmacies, the patients they care for, the communities they serve, and to #endPBMabuse
Minnesota, USA
Joined April 2024
- Tweets119
- Following77
- Followers51
- Likes168
MNIndys retweeted
CVS says it’s breaking up. Don’t be fooled.
CVS could still own your health insurance, pharmacy middleman, doctor’s office, and specialty pharmacy.
We need to break up Big Medicine once and for all.
MNIndys retweeted
CVS sees the writing on the wall: Americans want to break up the giant corporations dominating health care.
But this CEO is not fooling us—this lets CVS continue to own a massive conglomerate and rip people off.
We must break up these monopolies and put patients over profits.
The CEO of CVS says @SenWarren and @HawleyMO's Break Up Big Medicine bill is one of the reasons the company is breaking up! 👏
MNIndys retweeted
who knew that United Healthcare owned a big internet media company. What could go wrong ?
sunlightreportinsurance.com/…
MNIndys retweeted
The disconnect between the list prices and real prices of prescription drugs hits more than $400 billion NBD
Brand drug list prices rose 3.7% in 2025, but net prices fell 1.8%.
The GTN bubble is estimated to be $416 billion for 2025.
---
We’re revisiting Adam Fein's analysis this week as we put the finishing touches on the 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Grab your copy here! drugch.nl/wholesale
---
Adam breaks down gross-to-net pricing trends across eight large brand-name manufacturers for 2025 in the blog rerun this morning.
Nearly every manufacturer in this analysis had net price growth at or below U.S. consumer inflation of 2.6%.
Among the three manufacturers that disclosed average discount data, the average reduction from list price was 51.7%. The gross-to-net bubble is still expanding, but at its slowest rate on record.
Sanofi's numbers are particularly insightful as the most detailed and show the beginning of the Net Pricing Drug Channel (#NPDC).
Read the full analysis here 👉🏻 drugch.nl/3TIjC0n
MNIndys retweeted
Opened a rebate report this week that proudly said "100% pass-through." A PBM-owned aggregator had already taken its cut upstream. 100% of what was left is still 100%. The math was honest. The noun wasn't.
MNIndys retweeted
Vice President of Public Policy @_APCI @Greg_Reybold: "I would posit that what Express Scripts did in the TRICARE Retail Network is the poster child for why PBMs should not be allowed to own pharmacies."
MNIndys retweeted
WATCH: @SenWarren questions DHA Deputy Director Dr. Smith on the DOD's contract with Express Scripts.
"Why on earth is DOD requiring vertical integration so that the very company that's supposed to be doing the managing also owns this pharmacy that is competing with our independent pharmacies?"
Replying to @Jolleyben
Dr. Smith agrees to look into whether they should break up the vertical integration.
MNIndys retweeted
This is Eleanor and she really, really hopes @RepYassAnsari @EliCrane_CEO @RepAndyBiggsAZ and @DrPaulGosar support HR 6610 at tomorrow’s @HouseOversight meeting! Please don’t let her down!! @TruthRX
APCI's Greg Reybold is scheduled to testify tomorrow in a Senate subcommittee hearing regarding the TRICARE Pharmacy program. Click the link below tomorrow, July 15, at 2:30 PM EDT to watch the hearing.
ow.ly/47mI50ZmXeS
MNIndys retweeted
My wife and I own a pharmacy. Last month we spent days trying to pry one prescription loose from a company that did everything it could to hold onto it.
The drug was everolimus. A generic. It treats cancer and protects transplant patients from rejecting their new organ. Not exotic. Not rare. A pill.
The patient wanted it filled with us because we're cash-pay and cost-plus. No insurance. No PBM. No secret markups, no games. Our price was $318. That's not cheap by our standards — most of what we fill runs under $20 — but it was honest.
Here's what that same prescription looked like on the other side of the counter.
In 2023, Medicare was paying about $6,645 for it. That's roughly 21 times our price for the identical medication. Medicare spent around $240 million on everolimus alone that year. If they'd paid our price, they'd have saved roughly $230 million. On one generic drug.
So how does an insurance company profit off a drug that expensive? Don't they pay for it?
No. You pay for it. In your premiums. Their job isn't to spend less — it's to keep your healthcare dollars circulating inside their own companies. And the tool they use is called spread pricing.
Spread pricing works like this: the middleman bills the health plan one price, pays the pharmacy a lower one, and keeps the difference. You never see it. On TRICARE, they pay an independent pharmacy like mine about $311 to fill everolimus. That barely covers our cost of the drug. Meanwhile the plan gets billed thousands. That gap — north of $6,000 on a single fill — is pure margin the middleman pockets.
Now here's the part they'd rather you not think about.
The pharmacy we were fighting was Accredo. Accredo is owned by Express Scripts. Express Scripts is the pharmacy benefit manager owned by Cigna. Same company, three masks. That nesting-doll structure isn't an accident — it's the whole design. When the pharmacy, the PBM, and the insurer are all one entity, they can shuffle money between their own pockets and call it whatever they want. The confusion is the product.
And this isn't a story about one weird drug. It's the business model.
The FTC has been digging into exactly this. In its January 2025 report on the three biggest PBMs — CVS Caremark, Express Scripts, and OptumRx — staff found those companies marked up specialty generic drugs by hundreds and thousands of percent when dispensing through their own affiliated pharmacies. Just those markups generated more than $7.3 billion above what the drugs actually cost to acquire, from 2017 to 2022. One in five of the specialty generics they studied was marked up over 1,000%. Some cancer generics: over 3,000%. On top of that, the FTC pegged spread pricing on those same drugs at another $1.4 billion.
One example straight from the FTC's files: dimethyl fumarate, a multiple sclerosis drug. Costs about $177 to acquire. The PBMs paid their own pharmacies close to $4,000 for a 30-day supply. Same trick. Different drug.
And they steer the profitable ones to themselves on purpose. Pharmacies affiliated with the big three took in 68% of specialty dispensing revenue in 2023 — up from 54% in 2016. The prescriptions marked up more than $1,000 disproportionately end up at their own pharmacies, not independents like mine.
So when we called to transfer this patient's everolimus to be filled without insurance, it landed like we were asking them to set $6,000 on fire. Of course they stonewalled us.
That's why we fired them.
No insurance means no invisible $6,000 charge buried in a premium you can't itemize. It means the price you see is the price. Ours was $318. Theirs was thousands. Same pill.
MNIndys retweeted
I already know the answer to this, but I would like to know why Medicare Part D plans don’t cover generic Restasis.
Brand name Restasis costs $630 a month.
The generic costs roughly $30 a month.
We need to end PBM kick-back exemptions.
MNIndys retweeted
Replying to @heathercloud
@heathercloud, we couldn't have said it better ourselves 👏👏 #lalege
MNIndys retweeted
The most underrated corruption taking place in America's healthcare system is the fact that Aetna Insurance is owned by CVS Pharmacy
Yes, you read that right
The pharmacy that sells you the drugs is in bed with the insurance company that "covers" those drugs
They manipulate the prices and have all the patient data to make the most profitable decisions
Not enough people are talking about this.
100% should be illegal for a pharmacy and an insurance company to be owned by the same company
MNIndys retweeted
If insurance companies can deny care and call it "medically unnecessary", why aren't they required to have malpractice insurance doe when they get it wrong and someone gets sicker or tragically dies ?
Illinois needs to enforce bans on spread pricing by #PBMs and MCOs in the Medicaid program. | @regionalmediaqc
ow.ly/ef7150YMBt3
MNIndys retweeted
THE TRUTH CVS DOESN'T WANT YOU TO HEAR
I spoke with Benjamin Jolley, a rural independent pharmacist and expert on pharmacy benefit managers, about why CVS is pulling out all of the stops in Tennessee to stop HB1959/SB 2040 from passing.
MNIndys retweeted
WATCH: @RepHarshbarger calls out how the 340B Drug Pricing Program encourages higher costs for taxpayers and increases consolidation of health care providers.
This program offers a lifeline to safety net providers across the country, but over time has been abused to hurt taxpayers and benefit providers.
MNIndys retweeted
Nope. Not true. 46brooklyn.com/news/trump-sa…






















